2024年8月，国际知名学术期刊《Cureus》上发表的一项临床病例报告，详细记录了一位61岁晚期肝细胞癌患者在接受联合NK细胞治疗方案（DC疫苗+NK细胞+纳武利尤单抗）后，病情得到显著改善。其中，肝脏储备功能显著改善，肝部肿瘤体积大幅减小，为后续 ...

The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse ...

NKGen Biotech (NKGN) announced the publication of results from the Company’s initial dose escalation Phase 1 clinical trial of troculeucel, an ...

A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...

SANTA ANA, Calif. - NKGen Biotech, Inc. (NASDAQ: NKGN), a clinical-stage biotechnology company with a current market capitalization of $17 million, has received Fast Track designation from the U.S.

INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the ...

A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.

At JP Morgan last month, pharmaphorum editor-in-chief Jonah Comstock caught up with Paul Hastings, the CEO of Nkarta, to talk ...

CARsgen’s first enrolled subject in the THANK-u Plus platform-based allogeneic CAR-T trial achieves sCR at week 4: Shanghai, China Tuesday, February 11, 2025, 18:00 Hrs [IST] CA ...